 The purpose of this study is to assess the effect of a moderate Cytochrome P450 CYP 3A inhibitor erythromycin and a strong CYP3A inhibitor voriconazole on the steady-state pharmacokinetics PK the study of the way a drug enters and leaves the blood and tissues over time of repeated oral doses of ibrutinib in participants with B-cell malignancy cancer or other progressively enlarging and spreading tumors. 